Literature DB >> 26567141

PD-1 Blunts the Function of Ovarian Tumor-Infiltrating Dendritic Cells by Inactivating NF-κB.

Lavakumar Karyampudi1, Purushottam Lamichhane2, James Krempski3, Kimberly R Kalli4, Marshall D Behrens3, Doris M Vargas3, Lynn C Hartmann4, Jo Marie T Janco5, Haidong Dong3, Karen E Hedin3, Allan B Dietz6, Ellen L Goode7, Keith L Knutson8.   

Abstract

The PD-1:PD-L1 immune signaling axis mediates suppression of T-cell-dependent tumor immunity. PD-1 expression was recently found to be upregulated on tumor-infiltrating murine (CD11c(+)CD11b(+)CD8(-)CD209a(+)) and human (CD1c(+)CD19(-)) myeloid dendritic cells (TIDC), an innate immune cell type also implicated in immune escape. However, there is little knowledge concerning how PD-1 regulates innate immune cells. In this study, we examined the role of PD-1 in TIDCs derived from mice bearing ovarian tumors. Similar to lymphocytes, TIDC expression of PD-1 was associated with expression of the adapter protein SHP-2, which signals to NF-κB; however, in contrast to its role in lymphocytes, we found that expression of PD-1 in TIDC tonically paralyzed NF-κB activation. Further mechanistic investigations showed that PD-1 blocked NF-κB-dependent cytokine release in a SHP-2-dependent manner. Conversely, inhibition of NF-κB-mediated antigen presentation by PD-1 occurred independently of SHP-2. Collectively, our findings revealed that PD-1 acts in a distinct manner in innate immune cells compared with adaptive immune cells, prompting further investigations of the signaling pathways controlled by this central mediator of immune escape in cancer. ©2015 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26567141      PMCID: PMC4715980          DOI: 10.1158/0008-5472.CAN-15-0748

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  54 in total

1.  PD-1 immunoreceptor inhibits B cell receptor-mediated signaling by recruiting src homology 2-domain-containing tyrosine phosphatase 2 to phosphotyrosine.

Authors:  T Okazaki; A Maeda; H Nishimura; T Kurosaki; T Honjo
Journal:  Proc Natl Acad Sci U S A       Date:  2001-11-06       Impact factor: 11.205

Review 2.  TLR signalling regulated antigen presentation in dendritic cells.

Authors:  Colin Watts; Michele A West; Rossana Zaru
Journal:  Curr Opin Immunol       Date:  2010-01-18       Impact factor: 7.486

3.  Selective effects of PD-1 on Akt and Ras pathways regulate molecular components of the cell cycle and inhibit T cell proliferation.

Authors:  Nikolaos Patsoukis; Julia Brown; Victoria Petkova; Fang Liu; Lequn Li; Vassiliki A Boussiotis
Journal:  Sci Signal       Date:  2012-06-26       Impact factor: 8.192

4.  Expression of the PD-1 antigen on the surface of stimulated mouse T and B lymphocytes.

Authors:  Y Agata; A Kawasaki; H Nishimura; Y Ishida; T Tsubata; H Yagita; T Honjo
Journal:  Int Immunol       Date:  1996-05       Impact factor: 4.823

5.  Safety, activity, and immune correlates of anti-PD-1 antibody in cancer.

Authors:  Suzanne L Topalian; F Stephen Hodi; Julie R Brahmer; Scott N Gettinger; David C Smith; David F McDermott; John D Powderly; Richard D Carvajal; Jeffrey A Sosman; Michael B Atkins; Philip D Leming; David R Spigel; Scott J Antonia; Leora Horn; Charles G Drake; Drew M Pardoll; Lieping Chen; William H Sharfman; Robert A Anders; Janis M Taube; Tracee L McMiller; Haiying Xu; Alan J Korman; Maria Jure-Kunkel; Shruti Agrawal; Daniel McDonald; Georgia D Kollia; Ashok Gupta; Jon M Wigginton; Mario Sznol
Journal:  N Engl J Med       Date:  2012-06-02       Impact factor: 91.245

6.  Tumor-promoting immune-suppressive myeloid-derived suppressor cells in the multiple myeloma microenvironment in humans.

Authors:  Güllü Topal Görgün; Gregory Whitehill; Jennifer L Anderson; Teru Hideshima; Craig Maguire; Jacob Laubach; Noopur Raje; Nikhil C Munshi; Paul G Richardson; Kenneth C Anderson
Journal:  Blood       Date:  2013-01-15       Impact factor: 22.113

7.  Prognostic value of tumor-infiltrating dendritic cells expressing CD83 in human breast carcinomas.

Authors:  Mitsuhiko Iwamoto; Hisashi Shinohara; Akiko Miyamoto; Masaaki Okuzawa; Hideaki Mabuchi; Takehiro Nohara; Goki Gon; Masao Toyoda; Nobuhiko Tanigawa
Journal:  Int J Cancer       Date:  2003-03-10       Impact factor: 7.396

8.  Helicobacter pylori cytotoxin-associated gene A impairs human dendritic cell maturation and function through IL-10-mediated activation of STAT3.

Authors:  Romy Kaebisch; Raquel Mejías-Luque; Christian Prinz; Markus Gerhard
Journal:  J Immunol       Date:  2013-11-29       Impact factor: 5.422

9.  Neu antigen-negative variants can be generated after neu-specific antibody therapy in neu transgenic mice.

Authors:  Keith L Knutson; Bond Almand; Yushe Dang; Mary L Disis
Journal:  Cancer Res       Date:  2004-02-01       Impact factor: 12.701

10.  Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer.

Authors:  Lin Zhang; Jose R Conejo-Garcia; Dionyssios Katsaros; Phyllis A Gimotty; Marco Massobrio; Giorgia Regnani; Antonis Makrigiannakis; Heidi Gray; Katia Schlienger; Michael N Liebman; Stephen C Rubin; George Coukos
Journal:  N Engl J Med       Date:  2003-01-16       Impact factor: 91.245

View more
  44 in total

Review 1.  NF-κB signaling pathway and its potential as a target for therapy in lymphoid neoplasms.

Authors:  Li Yu; Ling Li; L Jeffrey Medeiros; Ken H Young
Journal:  Blood Rev       Date:  2016-10-13       Impact factor: 8.250

Review 2.  Molecular mechanisms involved in dendritic cell dysfunction in cancer.

Authors:  Michael Tang; Jun Diao; Mark S Cattral
Journal:  Cell Mol Life Sci       Date:  2016-08-05       Impact factor: 9.261

3.  Tumor-associated macrophages-additional effectors at anti-PD-1/PD-L1 therapy?

Authors:  Kenichi Suda
Journal:  J Thorac Dis       Date:  2017-11       Impact factor: 2.895

Review 4.  Tumor microenvironmental influences on dendritic cell and T cell function: A focus on clinically relevant immunologic and metabolic checkpoints.

Authors:  Kristian M Hargadon
Journal:  Clin Transl Med       Date:  2020-01

Review 5.  Mechanism-based treatment of cancer with immune checkpoint inhibitor therapies.

Authors:  Yara Abdou; Manu Pandey; Maithreyi Sarma; Shrunjal Shah; Jeffrey Baron; Marc S Ernstoff
Journal:  Br J Clin Pharmacol       Date:  2020-05-12       Impact factor: 4.335

6.  Dynamic interplay between tumour, stroma and immune system can drive or prevent tumour progression.

Authors:  R J Seager; Cynthia Hajal; Fabian Spill; Roger D Kamm; Muhammad H Zaman
Journal:  Converg Sci Phys Oncol       Date:  2017-07-28

7.  Immune checkpoint blockade reveals the stimulatory capacity of tumor-associated CD103(+) dendritic cells in late-stage ovarian cancer.

Authors:  Dallas B Flies; Tomoe Higuchi; Jaryse C Harris; Vibha Jha; Phyllis A Gimotty; Sarah F Adams
Journal:  Oncoimmunology       Date:  2016-05-13       Impact factor: 8.110

Review 8.  NF-κB, inflammation, immunity and cancer: coming of age.

Authors:  Koji Taniguchi; Michael Karin
Journal:  Nat Rev Immunol       Date:  2018-01-22       Impact factor: 53.106

9.  IL10 Release upon PD-1 Blockade Sustains Immunosuppression in Ovarian Cancer.

Authors:  Purushottam Lamichhane; Lavakumar Karyampudi; Barath Shreeder; James Krempski; Deborah Bahr; Joshua Daum; Kimberly R Kalli; Ellen L Goode; Matthew S Block; Martin J Cannon; Keith L Knutson
Journal:  Cancer Res       Date:  2017-10-09       Impact factor: 12.701

Review 10.  State-of-the-art of regulatory dendritic cells in cancer.

Authors:  Jose R Conejo-Garcia; Melanie R Rutkowski; Juan R Cubillos-Ruiz
Journal:  Pharmacol Ther       Date:  2016-04-23       Impact factor: 12.310

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.